## **Preventive Care Services - 2024**

The Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act of 2010 (HCERA) has designated the services listed below as preventive benefits and available with no cost-sharing when provided by an in-network provider. This information is intended as a reference tool for your convenience and is not a guarantee of payment. This guide is subject to change based on new or revised laws and/or regulations, additional guidance and/or medical policy.

\*\*Services are still subject to Medical Management Criteria\*\*

## **Wellness Examinations**

Preventive Care Services that may be provided during a Wellness Examination:

- ➤ Administration/Interpretation of Health Risk
- ➤ Assessment Instrument
- ➤ Anxiety screening
- ➤ Autism screening
- ➤ Blood pressure measurement for high blood pressure screening/Preeclampsia screening
- ➤ Breast-feeding counseling/support
- ➤ Counseling/education to minimize exposure to ultraviolet radiation
- ➤ Counseling to prevent initiation of tobacco use
- ➤ Counseling related to sexual behavior/sexually transmitted infection (STI) prevention including HIV Preexposure Prophylaxis (PrEP) related adherence counseling and pre- and postprescription follow up counseling
- ➤ Critical congenital heart disease screening
- ➤ Depression screening/Maternal Depression screening

- ➤ Discussion of aspirin prophylaxis
- ➤ Discussion of chemoprevention with women at risk for breast cancer
- ➤ Discussion/referral for genetic counseling/evaluation for BRCA testing
- ➤ Hearing and vision screening
- ➤ Intimate partner/interpersonal and domestic violence screening/referral to support services
- ➤ Obesity screening/counseling regarding weight loss, healthy diet and exercise
- ➤ Oral health assessment/discussion of water fluoridation/referral to dental home
- ➤ Psychosocial/Behavioral assessment
- ➤ Tobacco use screening/counseling
- ➤ Unhealthy Alcohol use and substance abuse screening/counseling
- ➤ Urinary incontinence screening

All applicable diagnosis codes for preventive services should be billed in the **primary position** on the claim as benefits are based on the primary diagnosis billed with the corresponding procedure code(s).

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Abdominal Aortic Aneurysm, Screening  USPSTF Rating (Dec. 2019): B The USPSTF recommends 1-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65-75 years who have ever smoked	76706	Routine diagnosis list F17.210, F17.211, F17.213, F17.218, F17.219, Z87.891	Males age 65 - 75 years One per lifetime

Preventive Service	Procedure Code(s)	Diagnosis	Limitations
Anemia Screening in Children  Bright Futures Recommends anemia screening for children under the age of 21 years of age which includes hemoglobin and hematocrit screening.	85013, 85014, 85018, 85025, 85027, 85041, G0306, G0307	Code(s)  Routine diagnosis list	Birth to age 21. No frequency limit.
Anxiety Disorders in Adults: Screening  USPSTF Rating (Jun. 2023): B The USPSTF recommends screening for	96127, 96160, 96161  For depression and suicide screening in Adults, see	Routine diagnosis list	
anxiety disorders in adults, including pregnant and postpartum persons.  Anxiety in Children and Adolescents	Depression and Suicide Risk in Adults: (Screening) 96127, 96160, 96161	Routine	
(Screening)	, ,	diagnosis list	
USPSTF Rating (Oct. 2022): The USPSTF recommends screening for anxiety in children and adolescents aged 8 to 18 years.	For depression screening in children and adolescents, see Depression and suicide risk in Children and Adolescents (Screening)		
Aspirin Use Preventive Medication	<i>y</i>		For aspirin prophylaxis, refer to Rx
USPSTF Rating (Sept. 2021): B The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in persons who are at high risk for preeclampsia.			plan
USPSTF Rating (Apr. 2022): C The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-			
dose aspirin daily are more likely to benefit.  Bacteriuria Screening	81007, 87086, 87088	Pregnancy	Pregnant women
USPSTF Rating (Sept. 2019): A The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons.	01001, 01000, 01000	diagnosis list	Tregnant women
Breast Cancer/Ovarian Cancer risk assessment: Genetic counseling for women at risk  See BRCA1/BRCA2 below for USPSTF rating and recommendation	96040, 99401 - 99404, \$0265	Z15.01, Z15.02, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44	Females only Two per lifetime

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
BRCA1/BRCA2 Genetic Testing for susceptibility to breast or ovarian cancer, if indicated: Women  USPSTF Rating (Aug. 2019): B The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.	81162 - 81167, 81212, 81215, 81216, 81217	Z15.01, Z15.02, Z80.3, Z80.41, Z85.3, Z85.43, Z85.44	Prior authorization requirements are waived when billed with the listed diagnosis codes.
Breast Cancer Screening  USPSTF Rating (Jan. 2016): B The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.  HRSA Requirement (Dec. 2016): Recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography screening; however, recommendations for additional services are beyond the scope of this recommendation.	77063**, 77065, 77066, 77067  Rev code: 0403	Routine diagnosis list	One annually for females age 40 and up  **77063 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Breast Cancer Prevention Medication	Rx only	0040(0)	For breast cancer prevention medication, refer to the Rx plan.
USPSTF Rating (Sept. 2019): B The USPSTF recommends that clinicians offer to prescribe risk reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.			
Breastfeeding Services and Supplies	Breastfeeding Equipment & Supplies:	Pregnancy diagnosis list	In conjunction with each birth from a DME supplier
USPSTF Rating (Oct. 2016): B The USPSTF recommends providing interventions during pregnancy and after birth to support breastfeeding.  HRSA Requirement (Dec. 2016): Recommends comprehensive lactation support services (including counseling, education, and breastfeeding equipment and supplies) during the antenatal, perinatal, and postpartum periods to ensure the successful initiation and maintenance of breastfeeding.	Breast Pumps (Manual & Electric): E0602RR E0603RR, for rental. E0602NU & E0603NU for purchase  Breast Pump (Hospital grade): E0604RR** Only available with high-risk diagnosis  Breast Pump Supplies: A4281, A4282, A4283, A4284, A4285, A4286  Counseling and Education: 99401 - 99404, 99411, 99412, S9443	N61.1, N64.4, N64.51 - N64.59, N64.89, O91.011 - O91.119, O91.13 - O92.5, O92.70 - O92.79, Q83.1 - Q83.8, Z39.1, Z39.2	**E0604RR, rental only with codes P05.00 - P07.39, P27.0 - P27.9, P29.30, P29.38, P92.1 - P92.9, Q20.0 - Q37.9, Q38.1 - Q38.3, Q90.0 - Q91.7, Q93.3 - Q93.9, R63.30 - R63.39, Z64.1

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Cervical Cancer Screening (Includes HPV)  USPSTF Rating (Aug. 2018): A The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21-29 years.  For women aged 30 to 65 years, the USPSTF recommends: Screening every 3 years with cervical cytology alone, Every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or Every 5 years with hrHPV testing in combination with cytology (cotesting).  Bright Futures, March 2014: Adolescents should no longer be routinely screened for cervical dysplasia until age 21.  HRSA Requirement (Dec. 2016): Recommends cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years recommends cervical cancer screening using cervical cytology (Pap test) every 3 years. Cotesting with cytology and human	0500T, 87623, 87624, 87625, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155**, 88164, 88165, 88166, 88167, 88174, 88175, G0101, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, G0476, P3000, P3001, Q0091	Code(s) Routine diagnosis list	Females age 21 and up  **88155 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.
papillomavirus testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with cytology and human papillomavirus testing every 5 years or cytology alone every 3 years. Women who are at average risk should not be screened more than once every 3 years.			

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Chlamydia Infection Screening  USPSTF Rating (Sept. 2021): B The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. Notes: This recommendation applies to asymptomatic, sexually active adolescents and adults, including pregnant persons. Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years. Notes: This recommendation applies to all sexually active adolescents and adult women, including pregnant women.  Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years.	Chlamydia Infection Screening: 0353U, 86631, 86632, 87110, 87205, 87270, 87320, 87490, 87491, 87492, 87800, 87801, 87810  For STI Prevention Counseling see Sexually Transmitted Infection (STI) Prevention Counseling	Routine diagnosis list or pregnancy diagnosis list	
Cholesterol Screening (Lipid Disorders Screening): Children/Adolescents  Bright Futures (April 2014): Risk Assessment: Recommended at 24 mo, 4 years, 6 years, 8 years, 12 years, 13 years, 14 years, 15 years,16 years. Screening Lab Work: Conduct if risk assessment is positive, or, at the following intervals: once between age 9-11 years; once between age 17-21 years	80061, 82465, 83718, 83719, 83721, 83722, 84478	Routine diagnosis list	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Cholesterol Screening (Lipid Disorders Screening): Adults  USPSTF Rating (Aug. 2022): B The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater.  Bright Futures (April 2014): Risk Assessment: Recommended at	80061, 82465, 83718, 83719, 83721, 83722, 84478		Age 2 - 21 years Age 40–75 years annually For statin medications, refer to Rx plan
24 mo, 4 years, 6 years, 8 years, 12 years, 13 years, 14 years, 15 years, 16 years. Screening Lab Work: Conduct if risk assessment is positive, or, at the following intervals: once between age 9-11 years; once between age 17-21 years			

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
USPSTF Rating (May 2021): B The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years.  USPSTF Rating (May 2021): A The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years.	Fecal occult blood test (FOBT) & Fecal immunochemical test (FIT) G0328, 82270, 82274  Sigmoidoscopy G0104, G0106, 45330, 45331, 45333, 45338, 45346  Colonoscopy G0105, G0120, G0121, G0122, 44388, 44389, 44392, 44394, 45378, 45380, 45381, 45384, 45385, 45388, 45390, 45391, 45392  Computed tomographic (CT) colonography 74263  Barium enema (BE) (included in colonoscopy) 74270, 74280  Fecal DNA(Cologuard) 81528  Pre-Op/Consultation: S0285  Pathology: 88304, 88305  Anesthesia: 00811, 00812, 00813* 99152, 99153**, 99156, 99157, G0500  Facility Revenue Codes: 360, 490, 750 & 761	Routine diagnosis list *00813 only when billed with Z12.10, Z12.11, Z86.010	Fecal occult blood testing (FOBT)/fecal immunochemical test (FIT) annually; or  ➤ Sigmoidoscopy every five years; or  ➤ Colonoscopy every 10 years; or  ➤ Computed tomographic colonoscopy) every five years; or  ➤ Double contrast barium enema (DCBE) every five years  ➤ Stool-based deoxyribonucleic acid (DNA) (i.e., Cologuard) every three years  Follow up colonoscopy after any positive non-invasive stool-based screening test or direct visualization screening test listed in USPSTF recommendation.  For Bowel Prep Products for Colorectal Cancer Screenings, refer to Rx plan.  **99153 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Depression and Suicide Risk in Adults: (Screening)	96127, 96161, G0444	Routine diagnosis list	
USPSTF Rating (Jun. 2023): B The USPSTF recommends screening for depression in the adult population, including pregnant and postpartum persons, as well as older adults.			
USPSTF Rating (Feb. 2019): B The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions.			
HRSA Requirement (Dec. 2019): The Women's Preventive Services Initiative recommends screening for anxiety in adolescent and adult women, including those who are pregnant or postpartum. Optimal screening intervals are unknown and clinical judgement should be used to determine screening frequency. Given the high prevalence of anxiety disorders, lack of recognition in clinical practices, and multiple problems associated with untreated anxiety, clinicians should consider	Maternal/Perinatal depression screening: 96156, 96158, 96159**, 96160, 96161, 96164, 96165, 96167, 96168	Pregnancy diagnosis list or F05, F30.XX, F34.1, F32.9, F53.0 – F53.1, G47.9, R53.81, R53.83, R45	**96159 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.
screening women who have not been recently screened.	Maternal/Perinatal depression counseling interventions: 99202 - 99205, 99211 - 99215, 99401 - 99404, 99411, 99412, G0463	Z13.32 or Z39.2	
Depression and suicide risk in	96127, 96161, G0444	Routine	
Children and Adolescents (Screening)	, ,	diagnosis list	
USPSTF Rating (Oct. 2022): B The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years.			
Bright Futures (February 2017): Maternal Depression Screening: Routine screening for postpartum depression should be integrated into well- child visits at 1, 2, 4, and 6 months of age. Note: The Bright Futures Periodicity Schedule recommends depression screening begin at age 12-21 years.			

Preventive Service	Procedure Code(s)	Diagnosis	Limitations
Developmental/Behavioral Screening	96110, 96127, G0451, S0302	Code(s) Routine diagnosis list	Birth to age 3
Bright Futures:  ➤ A formal, standardized developmental screen is recommended during the 9 month visit.  ➤ A formal, standardized developmental screen is recommended during the 18 month visit, including a formal autism screen.  ➤ A formal, standardized autism screen is recommended during the 24 month visit.  ➤ A formal, standardized developmental screen is recommended during the 30 month visit.			
Diabetes (Type 2) Screening  USPSTF Rating (Aug. 2021): B The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.	Diabetes Screening: 82947, 82948, 82950, 82951, 82952**, 83036  For counseling, see Nutrition/Physical Activity Counseling, Behavioral Interventions for Cardiovascular, Obesity, and Pregnancy  For gestational diabetes, see Gestational Diabetes Mellitus Screening	Routine diagnosis list	**82952 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.
Fall Prevention: community dwelling adults age 65 years and older with risk factors  USPSTF Rating (April 2018): B The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls.	97110, 97112, 97116, 97161, 97162, 97163, 97164, 97530, G0151, G0159	Z91.81	Age 65 and up
Fluoride Application (Dental Caries)  USPSTF Rating (May 2014): B Children From Birth Through Age 5 Years. The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.  Bright Futures (April 2017): For those at high risk, consider application of fluoride varnish for caries prevention every 3 to 6 months between ages 6 months to 5 years.	Fluoride Application: 99188  Oral health risk assessment: 96160, 96161	Routine diagnosis list	Fluoride application: Birth to age 5 Oral health risk assessment: 6 months to 6 years For oral fluoride supplementation, refer to Rx plan

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Gestational Diabetes Mellitus Screening  USPSTF Rating (Aug. 2021): B The USPSTF recommends screening for gestational diabetes mellitus in asymptomatic pregnant women after 24 weeks of gestation.  HRSA Requirement (Dec. 2017) The Women's Preventive Services Initiative recommends women with a history of gestational diabetes mellitus (GDM) who are not currently pregnant and who have not previously been diagnosed with type 2 diabetes mellitus should be screened for diabetes mellitus. Initial testing should ideally occur within the first year postpartum and can be conducted as early as 4-6 weeks postpartum. Women with a negative initial postpartum screening test result should be rescreened at least every 3 years for a minimum of 10 years after pregnancy.	Gestational Diabetes Mellitus Screening: 82947, 82948, 82950, 82951, 82952**, 83036  For counseling, see Nutrition/Physical Activity Counseling, Behavioral Interventions for Cardiovascular, Obesity, and Pregnancy	Pregnancy diagnosis list	**82952 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.
Gonorrhea Screening  USPSTF Rating (Sept. 2014): B The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.  Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years.	0353U, 87590, 87591, 87592, 87801, 87592, 87801, 87850  Gonorrhea, Prophylactic Medication, Newborn No code available - usually administered as an ancillary charge while inpatient at time of delivery  For STI Prevention Counseling see Sexually Transmitted Infection (STI) Prevention Counseling	Routine diagnosis list or pregnancy diagnosis list	
Hearing Screening  Bright Futures (April 2017): Hearing Tests: Recommended at ages: Newborn; between 3-5 days to 2 months; 4 years; 5 years, 6 years; 8 years; 10 years; once between age 11-14 years; once between age 15-17 years; once between age 18-21 years; also recommended for those that have a positive risk assessment.	92550, 92551, 92552, 92553, 92558, 92567, 92568, 92579, 92582, 92583, 92587, 92588, 92650, 92651, 92652, 92653, V5008	Routine diagnosis list	Birth - 10 years: no more than 7 tests 11 years to 21 years: no more than 3 tests

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Hepatitis B Virus Infection Screening	Hepatitis B Virus Infection Screening: 86704, 86705, 86706, 87340, 87341, G0499	Routine diagnosis list or pregnancy diagnosis list	
Pregnant Women: USPSTF Rating (July 2019): A The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit.		ŭ	
Adolescents and Adults at Increased Risk for Infection: USPSTF Rating (Dec. 2020): B The USPSTF recommends screening for hepatitis B virus (HBV) infection in persons at high risk for infection.			
Hepatitis C Virus Infection Screening	Hepatitis C Virus Infection Screening: 86803, 86804, 87522, G0472	Routine diagnosis list or pregnancy diagnosis list	Adults age 18 - 79 years
USPSTF Rating (March 2020): B The USPSTF recommends screening for hepatitis C virus infection in adults aged 18-79 years.	00112	diagnosis iist	
Bright Futures (March 2021) Bright Futures recommends screening all individuals ages 18 to 79 years at least once for hepatitis C virus infection (HCV)			
High Blood Pressure Screening	Usually included as part of an office visit.	R03.0, Z01.30, Z01.31	
USPSTF Rating (April 2021):A The USPSTF recommends screening for hypertension in adults 18 years or older with office blood pressure measurement.	Ambulatory Blood Pressure Measurement: 93784, 93786, 93788 or 93790, <mark>99473, 99474</mark>		
The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.			

Preventive Service	Procedure Code(s)	Diagnosis	Limitations
1107711	LIN/ Cara aria m	Code(s)	No analisaid
HIV (Human Immunodeficiency	HIV Screening:	Z29.81	No age limit
Virus) Screening for Adolescents	86689, 86701, 86702, 86703, 87081, 87389,	Routine	
and Adults		diagnosis list	
	87390, 87391, 87534,	or pregnancy	
USPSTF Rating (June 2019): A The	87806, G0432, G0433,	diagnosis list	
USPSTF recommends that clinicians	G0435, G0475, S3645	Z71.7	
screen for HIV infection in: Adolescents	HIV Counseling: 99401-99402	2/1./	
and adults aged 15- 65 years. Younger	99401-99402		
adolescents and older adults who are at			
increased risk of infection should also be			
screened. All pregnant persons, including			
those who present in labor or at delivery			
whose HIV status is unknown.			
Note: Bright Futures recommends HIV			
screening lab work be conducted once			
between ages 15-18 years. Also			
recommended anytime between ages 11-			
14 years, and 19-21 years when a risk			
assessment is positive.			
HRSA Requirement (Dec. 2016):			
Recommends prevention education and			
risk assessment for human			
immunodeficiency virus (HIV) infection in			
adolescents and women at least annually			
throughout the lifespan. All women should			
be tested for HIV at least once during their			
lifetime. Additional screening should be			
based on risk, and screening annually or			
more often may be appropriate for			
adolescents and women with an increased			
risk of HIV infection. Screening for HIV is			
recommended for all pregnant women			
upon initiation of prenatal care with			
retesting during pregnancy based on risk			
factors. Rapid HIV testing is recommended for prograph women who prosent in active			
for pregnant women who present in active labor with an undocumented HIV status.			
Screening during pregnancy enables			
prevention of vertical transmission.			
prevention of vertical transmission.		<u> </u>	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
HIV, Pre-exposure Prophylaxis (PrEP)	Injectable medication (Apretude - Cabotegravir): J0739*	Z29.81	For PrEP medications, refer to Rx plan.
USPSTF Rating (Aug. 2023): A The USPSTF recommends that clinicians prescribe preexposure prophylaxis using effective antiretroviral therapy to persons who are at increased risk of HIV acquisition to decrease the risk of acquiring HIV.	The following services for baseline/follow-up testing and monitoring are included per the CDC PrEP guidelines:		
Note: This includes:  ➤ Kidney function testing (creatinine)  ➤ Serologic testing for hepatitis B and C	Kidney function testing (creatinine): 82565, 82575, 82610		
virus  ➤Testing for other STIs  ➤Pregnancy testing when appropriate  ➤Ongoing followup and monitoring including HIV testing every 3 months	Hepatitis B testing: For Hepatitis B testing, see Hepatitis B Virus Infection Screening		
morading the testing every 5 months	Hepatitis C testing: For Hepatitis C testing, see Hepatitis C Virus Infection Screening		
	HIV: For HIV screening and counseling, see HIV (Human Immunodeficiency Virus) Screening for Adolescents and Adults		
	STI Testing: For Sexually Transmitted Infection (STI) screenings, see Chlamydia Infection Screening, Gonorrhea Screening and Syphilis Screening		
	Pregnancy testing (when appropriate): 81025, 84702, 84703		
	E/M Office Visits 99202 – 99215, 99242 – 99244		
Lead Screening	Lead Screening: 83655	Routine diagnosis list	Age 6 months - 6 years. No frequency limit.
Bright Futures: Screening Lab Work: Conduct risk assessment or screening, as appropriate, at the following intervals: 12 mo and 24 mo.Risk Assessment, and Screening if positive: Recommended at 6 mo, 9mo, 12 mo, 18 mo, 24 mo, 3 years, 4 years, 5 years and 6 years.		Ü	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Lung Cancer Screening/Counseling  USPSTF Rating (March 2021): B The USPSTF recommends annual screening for lung cancer with lowdose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack- year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery	Counseling: G0296 Screening: 71271	Routine diagnosis list or F17.210, F17.211, F17.213, F17.218, F17.219	Ages 50 - 80 years annually with history of smoking
Newborn Screening	Bilirubin Screening: 82247,82248, 88720	Routine diagnosis list	
USPSTF Rating (March 2008): A Hypothyroidism Screening: Screening for congenital hypothyroidism in newborns.  USPSTF Rating (March 2008): A Phenylketonuria Screening: Screening for phenylketonuria (PKU) in newborns.  USPSTF Rating (Sept. 2007): A Sickle Cell Screening: Screening for sickle cell disease in newborns.  Bright Futures Recommends screening for critical congenital heart disease using pulse oximetry for newborns after 24 hours of age, before discharge from the hospital	Congenital Hypothyroidism Screening: 84436, 84437, 84443, 84439, S3620  Metabolic Screening Panel: 82017, 82136, 82261, 82759, 82760, 82775, 82776, 83020, 83498, 83516, 83789, 84030, 84437, 84443, 86355, S3620  Phenylketonuria Screening: 84030, S3620  Sickle Cell Screening: 83020, 83021, 83030, 83033, 83051, 85660, S3850  Other: 86359  Critical Congenital Heart Disease Screening: Included with facility fee  Gonorrhea Prophylactic Ocular Medication to Prevent Blindness: See Gonorrhea Screening		

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Nutrition/Physical Activity Counseling, Behavioral Interventions for Cardiovascular, Obesity, and Pregnancy  USPSTF Rating (Nov. 2020): B	Medical Nutrition Therapy or Counseling: 97802, 97803, 97804, G0270, G0271, S9470 Behavioral Counseling or	Routine diagnosis list, pregnancy diagnosis list or;	3 visits annually
The USPSTF recommends offering or referring adults with cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity.	Therapy: G0446, G0447, G0473, 0403T, 0488T	F17.210, F17.211, F17.213, F17.218, F17.219	
USPSTF Rating (Sept. 2018): B The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive multicomponent behavioral interventions.  USPSTF Rating (June 2017): B		E13.9, E66.01, E66.09, E66.1, E66.3, E66.8, E66.9, E78.00, E78.01, E78.1, E78.2, E78.3, E78.41, E78.49, E78.5, E88.81	
The USPSTF recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer or refer them to comprehensive, intensive behavioral interventions to promote improvements in weight status.		I10, I15.0 - I15.9, I16.0 - I16.9, I25.10, I25.110 - I25.119, I25.700 -	
USPSTF Rating (May 2021): B The USPSTF recommends that clinicians offer pregnant persons effective behavioral		125.812, I70.0 - 170.91 R73.01, N26.2	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
counseling interventions aimed at promoting healthy weight gain and preventing excess gestational weight gain in pregnancy.	Preventive Medicine Individual Counseling: 99401, 99402, 99403, 99404	F17.210, F17.211, F17.213, F17.218, F17.219	
		E08.00 - E13.9, E66.01, E66.09, E66.1, E66.3, E66.8, E66.9, E78.00, E78.01, E78.1, E78.2, E78.3, E78.41, E78.49, E78.5, E88.81	
		I10, I15.0 - I15.9, I16.0 - I16.9, I25.10, I25.110 - I25.119, I25.700 - I25.812, I70.0 - 170.91	
	70077 77070 77000	R73.01, N26.2	F
USPSTF Rating (June 2018): B Women 65 and older: The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.	76977, 77078, 77080, 77081, G0130	Routine diagnosis list	Females only
USPSTF Rating (June 2018): B Postmenopausal women younger than 65 years at increased risk of osteoporosis: The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.			
Prenatal Care	Prenatal Office Visits:	Pregnancy	Females only
USPSTF Rating (April 2017): B The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.	Evaluation and Management (Office Visits): 59425, 59426, 99202 - 99215, 99417**, G0463	diagnosis list	For folic acid supplements, refer to Rx plan  **99417 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS
			code.

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Rh incompatibility Screening  USPSTF Rating (Feb. 2004): A Rh (D) blood typing and antibody testing for all pregnant women during their first visit for pregnancyrelated care.	86900, 86901, 80055, 80081, 86850	Pregnancy diagnosis list	Females only
USPSTF Rating (Feb. 2004): B Repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24- 28 weeks' gestation, unless the biological father is known to be Rh (D)-negative			
Sexually Transmitted Infection (STI) Prevention Counseling	STIs Behavioral Counseling: G0445	Z71.7, Z71.89, Z72.51 - Z72.53	G0445 is limited to twice per year
USPSTF Rating (Aug. 2020): B The USPSTF recommends behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs).  HRSA Requirement (Dec. 2016): Recommends directed behavioral counseling by a health care provider or other appropriately trained individual for sexually active adolescent and adult women at an increased risk for STIs. This recommendation further recommends that health care providers use a woman's sexual history and risk factors to help identify those at an increased risk of STIs. Risk factors may include age younger than 25, a recent history of an STI, a new sex partner, multiple partners, a partner with concurrent partners, a partner with an STI, and a lack of or inconsistent condom use. For adolescents and women not identified as high risk, counseling to reduce the risk of STIs should be considered, as determined by clinical judgement.	Preventive Medicine Individual Counseling: 99401, 99402, 99403, 99404, 99411, 99412  Note: For Sexually Transmitted Infection (STI) screenings, see Chlamydia Infection Screening, Gonorrhea Screening and Syphilis Screening	212.33	
Skin Cancer Prevention: Behavioral Counseling			This service is included in a preventive care wellness examination or focused E&M visit.
USPSTF Rating (March 2018): B The USPSTF recommends counseling young adults, adolescents, children and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons ages 6 months to 24 years with fair skin types to reduce their risk of skin cancer.			

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Smoking and Tobacco Cessation Counseling/Interventions	99406, 99407	Any diagnosis code	For smoking cessation medications, refer to Rx plan
USPSTF Rating (Jan. 2021): A Pregnant Persons (A): The USPSTF recommends that clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant persons who use tobacco.			
Nonpregnant Adults (A):The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and US Food and Drug Administration (FDA)—approved pharmacotherapy for cessation to nonpregnant adults who use tobacco.			
USPSTF Rating (April 2013): B The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.			
Bright Futures (April 2017): Bright Futures recommends tobacco use assessments from age 11-21 years.			
Non-Pregnant Adults and Adolescents at Increased Risk: USPSTF Rating (Sept. 2022): A The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.	Syphilis Screening: 86592, 86593, 86780  For STI Prevention Counseling see Sexually Transmitted Infection (STI) Prevention Counseling	Routine diagnosis list or pregnancy diagnosis list	
Pregnant Women: USPSTF Rating (Sept. 2018): A The USPSTF recommends early screening for syphilis infection in all pregnant women.			
Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years.			

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Tuberculosis Screening  USPSTF Rating (Sept. 2016): B The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.  This recommendation applies to asymptomatic adults 18 years and older at increased risk for tuberculosis.	Screening: 86480, 86481, 86580 Follow-up Visit to Check Results: 99211	R76.11, R76.12, Z20.1, Z00.121, Z00.129, Z11.1, Z11.7, Z20.1, Z22.7, Z86.15	No age limit
Uspstf Rating (Nov. 2018): B The Uspstf recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.  Uspstf Rating (June 2020): B The Uspstf recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.)  Bright Futures (April 2017): Bright Futures recommends alcohol or drug use assessments from age 11-21 years.	Alcohol or Drug Use Screening: 99408, 99409, G0442, H0001 Counseling: G0396, G0397, G0443, G2011	Any diagnosis code	Age 11 and up annually

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Vision Screening  USPSTF Rating (Sept. 2017): B The USPSTF recommends vision screening at least once in all children age 3 to 5 years to detect amblyopia or its risk factors.  Bright Futures: Visual acuity screening is recommended for age 4 and 5 years as well as in cooperative 3 year olds.  Instrument-based screening recommended for age 12 and 24 months, in addition to the well visits at 3-5 years of age.  Bright Futures Visits Newborn, First Week; 1, 2, 4, 6, 9, 12, 15, 18 Month; 2, 2½, 7, 9, 11, 13, 14, 16, 17, 18 Through 21 Year	99172, 99173, 99174, 99177	Z01.00, Z01.01, Z00.129, Z00.121, Z00.110, Z00.111, Z13.5	Birth to age 21
Wellness Examinations  Preventive medicine comprehensive evaluation and management services for well-baby, well-child and well-adult, including well-woman include:  ➤ An age-and gender-appropriate history  ➤ Physical examination  ➤ Counseling/anticipatory guidance	Annual Wellness examinations: 99385 - 99387, 99395 - 99397, G0438, G0439, G0513**, G0514** Well-woman examinations: 99383 - 99387, 99393 - 99397, G0101, G0438, G0439, S0610 - S0613	Routine diagnosis list  Routine diagnosis list	Each Plan Year, a participant may choose a maximum of two of the following three services:  One annual examination with a primary care provider,  One annual well-woman examination (Females only beginning at age 10)
➤ Risk factor reduction interventions ➤ The ordering of appropriate immunization(s) and laboratory/screening procedures  Bright Futures Periodicity Schedule: ➤ Infancy (Newborn to 9mo): 7 visits ➤ Early Childhood (12mo to 4y): 7 visits ➤ Middle Childhood (5y to 10y): 6 visits ➤ Adolescence (11y to 21y): 11 visits	Natural Family Planning (includes preconception): 99202 - 99205, 99211 - 99215, 99401 - 99404	Z30.02, Z31.61, Z31.69	One natural family planning examination (Females only)  If a participant receives one or two of the foregoing services in a calendar year, the services will be covered as provided in the Plan. If a participant receives all three services in a Plan Year, only the first two services the participant receives

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
Bright Futures Periodicity Schedule:  ➤ Newborn to 9mo: 7 visits  ➤ 12mo to 30mo: 5 visits  ➤ 3y to 21y: 1 visit annually	Well-baby/Well-child examinations: 99381 – 99382***, 99383, 99384, 99391 – 99392***, 99393, 99394  Inpatient newborn care (physician services only): 99221-99223, 99231 - 99233, 99234 - 99236, 99238, 99239, 99460 - 99464, 99478 - 99480	Routine diagnosis list	will be covered as a preventive benefit.  **G0513/G0514 - Add-on code is allowed with no cost sharing when submitted in conjunction with an appropriate primary preventive CPT/HCPCS code.  ***Age 0 to age 5: Frequency according to the American Academy of Pediatrics (AAP) Bright Futures Periodicity Schedule
Blood Draw for Preventive Laboratory Services	36415, 36416	R76.11, R76.12, Routine diagnosis list, pregnancy diagnosis list	

## Contraceptives

Contraceptive Methods and Counseling HRSA Recommendation December 2019  HRSA Recommendation December 2019  The Women's Preventive Services Initiative recommends that adolescent and adult women have access to the full range of female-controlled contraceptives to prevent unintended pregnancy and improve birth outcomes. Contraceptive care should include contraceptive use, and follow-up care (e.g., management, and evaluation as well as changes to and removal or discontinuation of the contraceptive method). The Women's Preventive Services Initiative recommends that the full range of female-controlled U.S. Food and Drug Administration-approved contraceptive methods for women currently identified by the U.S. Food and Drug Administration include: (1) sterilization surgery for women, (2) surgical sterilization via implant for women, (3) implantable rods, (4) copper intrauterine devices with progestin (all durations and doses), (6) the shot or injection, (7) oral contraceptives (combined pill), 8) oral contraceptives (combined pill), 8) oral contraceptives (combined pill), 8) oral contraceptives (extended or continuous use), (10) the contraceptive patch, (11) vaginal contraceptive rings, (12) diaphragms, (13) contraceptive sponges, (14) cervical caps, (15) femaled with a specific procession of the contraceptive progession (12) diaphragms, (13) contraceptive progession, (14) cervical caps, (15) femaled with a specific procession of the contraceptive progession (12) diaphragms, (13) contraceptive progession, (14) cervical caps, (15) femaled with a specific procession of the contraceptive procession of the contracep	Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
HRSA Recommendation December 2019  The Women's Preventive Services Initiative recommends that adolescent and adult women have access to the full range of female-controlled contraceptives experience in the foundation of contraceptive care should include contraceptive counseling, initiation of contraceptive well as changes to and removal or discontinuation of the contraceptive method). The Women's Preventive Services Initiative recommends that full range of female-controlled U.S. Food and Drug Administration-approved contraceptive methods, effective family planning practices, and sterilization procedures be available as part of contraceptive experience, in the full range of formaticeptive methods, effective family planning practices, and sterilization procedures be available as part of contraceptive methods for women currently identified by the U.S. Food and Drug Administration include: (1) sterilization surgery for women, (2) surgical sterilization surgery for women, (2) surgical sterilization surgery for women, (2) surgical sterilization and doses), (6) the shot or injection, (7) oral contraceptives (combined pill), 8) oral contraceptive patch, (11) vaginal contraceptive stoppes, (14) cervical caps, (15)  Base 58565, 58600, 58611, 58700, 59525, A4264, Tubal Ligation Follow-up (only with diagnosis code 298.51) Hysterosalpingogram Catheterization and Introduction of Saline or Contrast Material: Q9967  Pathology: Patholog	Contraceptive Methods and Counseling	Sterilizations:		For oral
The Women's Preventive Services Initiative recommends that adolescent and adult women have access to the full range of female-controlled contraceptive care should include contraceptive cunseling, initiation of contraceptive use, and follow-up care (e.g., management, and evaluation as well as changes to and removal or discontinuation of the contraceptive method). The Women's Preventive Services Initiative recommends that the full range of female-controlled U.S. Food and Drug Administration-approved contraceptive methods, effective family planning practices, and sterilization procedures be available as part of contraceptive methods for women currently identified by the U.S. Food and Drug Administration include: (1) sterilization surgery for women, (2) surgical sterilization viamplant for women, (3) implantable rods, (4) copper intrauterine devices, (5) intrauterine devices with progestin (all durations and doses), (6) the shot or injection, (7) oral contraceptives (extended or continuous use), (10) the contraceptive patch, (11) vaginal contraceptive rings, (12) diaphragms, (13) contraceptive sponges, (14) cervical caps, (15) Devices and implants:	HRSA Recommendation December 2019	58565, 58600, 58605, 58611, 58615,	diagnosis list	contraception,
remale condoms, (16) spermicides, and (17) emergency contraception (levonorgestrel), and (18) emergency contraception (ulipristal acetate), and additional methods as identified by the FDA. Additionally, instruction in fertility awareness-based methods, including  J7307  J7294 - J7298  Injections: J1050 (injection) 96372 (administration)	HRSA Recommendation December 2019  The Women's Preventive Services Initiative recommends that adolescent and adult women have access to the full range of female-controlled contraceptives to prevent unintended pregnancy and improve birth outcomes. Contraceptive care should include contraceptive use, and follow-up care (e.g., management, and evaluation as well as changes to and removal or discontinuation of the contraceptive method). The Women's Preventive Services Initiative recommends that the full range of female-controlled U.S. Food and Drug Administration-approved contraceptive methods, effective family planning practices, and sterilization procedures be available as part of contraceptive care. The full range of contraceptive methods for women currently identified by the U.S. Food and Drug Administration include: (1) sterilization surgery for women, (2) surgical sterilization via implant for women, (3) implantable rods, (4) copper intrauterine devices, (5) intrauterine devices with progestin (all durations and doses), (6) the shot or injection, (7) oral contraceptives (combined pill), 8) oral contraceptives (progestin only, and), (9) oral contraceptives (extended or continuous use), (10) the contraceptive patch, (11) vaginal contraceptive rings, (12) diaphragms, (13) contraceptive rings, (12) diaphragms, (13) contraceptive rings, (12) diaphragms, (13) contraceptive sponges, (14) cervical caps, (15) female condoms, (16) spermicides, and (17) emergency contraception (levonorgestrel), and (18) emergency contraception (ulipristal acetate), and additionall methods as identified by the FDA. Additionally, instruction in	Tubal Ligation, Oviduct Occlusion: 58565, 58600, 58605, 58611, 58615, 58670, 58671, 58700, 59525, A4264,  Tubal Ligation Follow-up (only with diagnosis code Z98.51) Hysterosalpingogram Catheterization and Introduction of Saline or Contrast Material: 58340 Hysterosalpingography: 74740 Contrast Material: Q9967  Pathology: 88302  Anesthesia for Sterilization: 00851, 00940, 00942, 00950, 00952, 01960, 01961, 01965, 01966, 01967, 01968  Services for insertion/removal of intrauterine devices, implants; fitting diaphragm or cervical cap: 11976, 11981, 11982, 11983, 57170, 58300, 58301, A4261, A4266, S4981, S4989  Ultrasound guidance for IUD placement verification or guidance: 76830, 76856, 76857, 76998  Devices and implants: J7300 - J7307 J7294 - J7298  Injections: J1050 (injection)	diagnosis list	/emergency contraception, refer to Rx

## **Immunizations**

Immunization	Procedure Code(s)
COVID-19 Vaccine	91304, 91318, 91319, 91320, 91321, 91322
Dengue Vaccine - Children age 9 – 16 years	90587
Diphtheria, Tetanus, and Acellular Pertussis (DT/DTap) Vaccine	90696, 90697, 90698, 90700, 90702, 90723
Hepatits A (HepA) Vaccine	90632, 90633, 90634, 90636
Hepatits B (HepB) Vaccine	90739, 90740, 90743, 90744, 90746, 90747, 90748, 90759
Haemophilus Influenzae Type B (Hib) Vaccine	90647, 90648
Human Papillomavirus (HPV) Vaccine	90649, 90650, 90651
Influenza (IIV, LAIV4, RIV4) Vaccine	90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90664, 90666, 90667, 90668, 90672, 90673, 90674, 90682, 90685, 90687, 90688, 90689, 90694, 90756, Q2034, Q2035, Q2036, Q2037, Q2038, Q2039
Measles, Mumps, Rubella (MMR) and Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine	90707, 90710
Meningococcal(MenACWY, MenB) Vaccine	90619, 90620, 90621, 90644, 90733, 90734
Mpox Vaccine	90611
Pneumococcal (PCV13, PCV15, PCV20, PPSV23) Vaccine	90670, 90671, 90677, 90732
Polio (IPV) Vaccine	90713
Rotavirus (RV) Vaccine	90680, 90681
Respiratory syncytial virus (RSV) Vaccine	90380, 90381, 90678, 90679
Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Tdap/Td)	90714, 90715
Varicella (VAR) Vaccine	90716
Zoster (RZV) Vaccine - Shingrix	90750
Immunization Administration	90460, 90461, 90471, 90472, 90473, 90474, <mark>90480</mark> G0008, G0009, G0010, Rev code 0771

Routine Diagnosis List	
ICD-10 Code(s)	Description
Z00.00	Encounter for general adult medical examination without abnormal findings
Z00.01	Encounter for general adult medical examination with abnormal findings
Z00.110	Health examination for newborn under 8 days old
Z00.111	Health examination for newborn 8 to 28 days old
Z00.121	Encounter for routine child health examination with abnormal findings

	Routine Diagnosis List
ICD-10 Code(s)	Description
Z00.129	Encounter for routine child health examination without abnormal findings
Z00.3	Encounter for examination for adolescent development state
Z00.8	Encounter for other general examination
Z01.00	Encounter for examination of eyes and vision without abnormal findings
Z01.01	Encounter for examination of eyes and vision with abnormal findings
Z01.02	Encounter for examination of eyes and vision following failed vision screening
Z01.020	Encounter for examination of eyes and vision following failed vision screening without abnormal findings
Z01.021	Encounter for examination of eyes and vision following failed vision screening with abnormal findings
Z01.10	Encounter for examination of ears and hearing without abnormal findings
Z01.110	Encounter for hearing examination following failed hearing screening
Z01.118	Encounter for examination of ears and hearing with other abnormal findings
Z01.30	Encounter for examination of blood pressure without abnormal findings
Z01.31	Encounter for examination of blood pressure with abnormal findings
Z01.411	Encounter for gynecological examination (general) (routine) with abnormal findings
Z01.419	Encounter for gynecological examination (general) (routine) without abnormal findings
Z01.42	Encounter for cervical smear to confirm findings of recent normal smear following initial abnormal smear
Z02.83	Encounter for blood-alcohol and blood-drug test
Z11.0	Encounter for screening for intestinal infectious diseases
Z11.1	Encounter for screening for respiratory tuberculosis
Z11.2	Encounter for screening for other bacterial diseases (SYPHILIS)
Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission
Z11.4	Encounter for screening for human immunodeficiency virus [HIV]
Z11.51	Encounter for screening for human papillomavirus (HPV)
Z11.59	Encounter for screening for other viral diseases
Z11.6	Encounter for screening for other protozoal diseases and helminthiases
Z11.7	Encounter for testing for latent tuberculosis infection
Z11.8	Encounter for screening for other infectious and parasitic diseases
Z11.9	Encounter for screening for infectious and parasitic diseases, unspecified (GONORRHEA)
Z12.2	Encounter for screening for malignant neoplasm of respiratory organs
Z12.10	Encounter for screening for malignant neoplasm of intestinal tract, unspecified
Z12.11	Encounter for screening for malignant neoplasm of colon
Z12.12	Encounter for screening for malignant neoplasm of rectum

ICD-10 Code(s)	Description
740.40	
Z12.13	Encounter for screening for malignant neoplasm of small intestine
Z12.2	Encounter for screening for malignant neoplasm of respiratory organs
Z12.31	Encounter for screening mammogram for malignant neoplasm of breast
Z12.39	Encounter for other screening for malignant neoplasm of breast
Z12.4	Encounter for screening for malignant neoplasm of cervix
Z12.5	Encounter for screening for malignant neoplasm of prostate
Z12.72	Encounter for screening for malignant neoplasm of vagina
Z12.81	Encounter for screening for malignant neoplasm of oral cavity
Z13.0	Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Z13.1	Encounter for screening for diabetes mellitus
Z13.21	Encounter for screening for nutritional disorder
Z13.22	Encounter for screening for metabolic disorder
Z13.220	Encounter for screening for lipoid disorders
Z13.228	Encounter for screening for other metabolic disorders
Z13.29	Encounter for screening for other suspected endocrine disorder
Z13.31	Encounter for screening for depression
Z13.32	Encounter for screening for maternal depression
Z13.39	Encounter for screening examination for other mental health and behavioral disorders
Z13.40	Encounter for screening for unspecified developmental delays
Z13.41	Encounter for autism screening
Z13.42	Encounter for screening for global developmental delays (milestones)
Z13.49	Encounter for screening for other developmental delays
Z13.5	Encounter for screening for eye and ear disorders
Z13.6	Encounter for screening for cardiovascular disorders
Z13.820	Encounter for screening for osteoporosis
Z13.84	Encounter for screening for dental disorders
Z13.88	Encounter for screening for disorder due to exposure to contaminants
Z13.89	Encounter for screening for other disorder
Z15.01	Genetic susceptibility to malignant neoplasm of breast
Z15.02	Genetic susceptibility to malignant neoplasm of ovary
Z20.1	Contact with and (suspected) exposure to tuberculosis

////	Description  Contact with and (suspected) exposure to infections with a predominantly sexual mode of
////	Contact with and (suspected) exposure to infections with a predominantly sexual mode of
	transmission
Z20.5	Contact with and (suspected) exposure to viral hepatitis
Z20.6	Contact with and (suspected) exposure to human immunodeficiency virus [HIV]
Z22.7	Latent tuberculosis
Z23	Encounter for immunization
Z29.3	Encounter for prophylactic fluoride administration
Z57.8	Occupational exposure to other risk factors
Z63.6	Dependent relative needing care at home
Z63.79	Other stressful life events affecting family and household
Z68.25 - Z68.45	BMI 25+
Z69.010 - Z69.12	Encounter for mental health services for abuse
Z69.81	Encounter for mental health services for victim of other abuse
Z69.82	Encounter for mental health services for perpetrator of other abuse
Z71.3	Dietary counseling and surveillance
Z71.41	Alcohol abuse counseling and surveillance of alcoholic
Z71.42	Counseling for family member of alcoholic
Z71.51	Drug abuse counseling and surveillance of drug abuser
Z71.52	Counseling for family member of drug abuser
Z71.53	High risk bisexual behavior
Z71.6	Tobacco abuse counseling
Z71.7	Human immunodeficiency virus [HIV] counseling
Z71.82	Exercise counseling
Z71.83	Encounter for non-procreative genetic counseling
Z71.89	Other specified counseling
Z71.9	Counseling, unspecified
Z72.0	Tobacco use
Z72.51	High risk heterosexual behavior [effective 9/17/2021]
Z72.52	High risk homosexual behavior [effective 9/17/2021]
Z72.53	High risk bisexual behavior [effective 9/17/2021]
Z72.89	Other problems related to lifestyle
Z72.9	Problem related to lifestyle, unspecified

	Routine Diagnosis List
ICD-10 Code(s)	Description
Z73.9	Problem related to life management difficulty, unspecified
Z76.1	Encounter for health supervision and care of foundling
Z76.2	Encounter for health supervision and care of other healthy infant and child
Z76.81	Expectant parent(s) prebirth pediatrician visit
Z76.89	Persons encountering health services in other specified circumstances
Z77.011	Contact with and (suspected) exposure to lead
Z80.0	Family history of malignant neoplasm of digestive organs
Z80.3	Family history of malignant neoplasm of breast
Z80.41	Family history of malignant neoplasm of ovary
Z80.42	Family history of malignant neoplasm of prostate
Z82.49	Family history of ischemic heart disease and other diseases of the circulatory system
Z82.62	Family history of osteoporosis
Z83.3	Family history of diabetes mellitus
Z83.42	Family history of familial hypercholesterolemia
Z83.710	Family history of adenomatous and serrated polyps
Z83.711	Family history of hyperplastic colon polyps
Z83.718	Other family history of colon polyps
Z83.719	Family history of colon polyps, unspecified
Z83.79	Family history of other diseases of the digestive system
Z85.3	Personal history of malignant neoplasm of breast
Z85.43	Personal history of malignant neoplasm of ovary
Z85.44	Personal history of malignant neoplasm of other female genital organs
Z86.010	Personal history of colonic polyps
Z86.15	Personal history of latent tuberculosis infection
Z86.32	Personal history of gestational diabetes
Z86.39	Personal history of other endocrine, nutritional and metabolic disease
Z87.312	Personal history of (healed) stress fracture
Z87.81	Personal history of (healed) traumatic fracture
Z87.891	Personal history of nicotine dependence
Z90.79	Acquired absence of other genital organ(s)
Z91.81	History of falling
Z92.241	Personal history of systemic steroid therapy

Pregnancy Diagnosis List	
ICD-10 Code(s)	Description
O00.00 - O94.53	Pregnancy, Childbirth and the puerperium
P05.00 - P07.39	Disorders of newborn related to length of gestation and fetal growth
P27.0 - P27.9	Respiratory and cardiovascular disorders specific to the perinatal period
P92.1 - P92.9	Respiratory and cardiovascular disorders specific to the perinatal period
Z03.71	Encounter for suspected problem with amniotic cavity and membrane ruled out
Z03.72	Encounter for suspected placental problem ruled out
Z03.73	Encounter for suspected fetal anomaly ruled out
Z03.74	Encounter for suspected problem with fetal growth ruled out
Z03.75	Encounter for suspected cervical shortening ruled out
Z03.79	Encounter for other suspected maternal and fetal conditions ruled out
Z29.13	Encounter for prophylactic Rho(D) immune globulin
Z32.01	Encounter for pregnancy test, result positive
Z32.2	Encounter for childbirth instruction
Z33.1	Pregnant state, incidental
Z33.3	Pregnant state, gestational carrier
Z34.00	Encounter for supervision of normal first pregnancy, unspecified trimester
Z34.01	Encounter for supervision of normal first pregnancy, first trimester
Z34.02	Encounter for supervision of normal first pregnancy, second trimester
Z34.03	Encounter for supervision of normal first pregnancy, third trimester
Z34.80	Encounter for supervision of other normal pregnancy, unspecified trimester
Z34.81	Encounter for supervision of other normal pregnancy, first trimester
Z34.82	Encounter for supervision of other normal pregnancy, second trimester
Z34.83	Encounter for supervision of other normal pregnancy, third trimester
Z34.90	Encounter for supervision of normal pregnancy, unspecified, unspecified trimester
Z34.91	Encounter for supervision of normal pregnancy, unspecified, first trimester
Z34.92	Encounter for supervision of normal pregnancy, unspecified, second trimester
Z34.93	Encounter for supervision of normal pregnancy, unspecified, third trimester
Z36.0	Encounter for antenatal screening for chromosomal anomalies

	Pregnancy Diagnosis List
ICD-10 Code(s)	Description
Z36.1	Encounter for antenatal screening for raised alphafetoprotein level
Z36.2	Encounter for other antenatal screening follow-up
Z36.3	Encounter for antenatal screening for malformations
Z36.4	Encounter for antenatal screening for fetal growth retardation
Z36.5	Encounter for antenatal screening for isoimmunization
Z36.81	Encounter for antenatal screening for hydrops fetalis
Z36.82	Encounter for antenatal screening for nuchal translucency
Z36.83	Encounter for fetal screening for congenital cardiac abnormalities
Z36.84	Encounter for antenatal screening for fetal lung maturity
Z36.85	Encounter for antenatal screening for Streptococcus B
Z36.86	Encounter for antenatal screening for cervical length
Z36.87	Encounter for antenatal screening for uncertain dates
Z36.88	Encounter for antenatal screening for fetal macrosomia
Z36.89	Encounter for other specified antenatal screening
Z36.8A	Encounter for antenatal screening for other genetic defects
Z36.9	Encounter for antenatal screening, unspecified
Z39.1	Encounter for care and examination of lactating mother
Z39.2	Encounter for routine postpartum follow-up
Z3A.00	Weeks of gestation of pregnancy not specified
Z3A.01	Less than 8 weeks gestation of pregnancy
Z3A.08	8 weeks gestation of pregnancy
Z3A.09	9 weeks gestation of pregnancy
Z3A.10	10 weeks gestation of pregnancy
Z3A.11	11 weeks gestation of pregnancy
Z3A.12	12 weeks gestation of pregnancy
Z3A.13	13 weeks gestation of pregnancy
Z3A.14	14 weeks gestation of pregnancy
Z3A.15	15 weeks gestation of pregnancy
Z3A.16	16 weeks gestation of pregnancy
Z3A.17	17 weeks gestation of pregnancy
Z3A.18	18 weeks gestation of pregnancy
Z3A.19	19 weeks gestation of pregnancy

Pregnancy Diagnosis List	
ICD-10 Code(s)	Description
Z3A.20	20 weeks gestation of pregnancy
Z3A.21	21 weeks gestation of pregnancy
Z3A.22	22 weeks gestation of pregnancy
Z3A.23	23 weeks gestation of pregnancy
Z3A.24	24 weeks gestation of pregnancy
Z3A.25	25 weeks gestation of pregnancy
Z3A.26	26 weeks gestation of pregnancy
Z3A.27	27 weeks gestation of pregnancy
Z3A.28	28 weeks gestation of pregnancy
Z3A.29	29 weeks gestation of pregnancy
Z3A.30	30 weeks gestation of pregnancy
Z3A.31	31 weeks gestation of pregnancy
Z3A.32	32 weeks gestation of pregnancy
Z3A.33	33 weeks gestation of pregnancy
Z3A.34	34 weeks gestation of pregnancy
Z3A.35	35 weeks gestation of pregnancy
Z3A.36	36 weeks gestation of pregnancy
Z3A.37	37 weeks gestation of pregnancy
Z3A.38	38 weeks gestation of pregnancy
Z3A.39	39 weeks gestation of pregnancy
Z3A.40	40 weeks gestation of pregnancy
Z3A.41	41 weeks gestation of pregnancy
Z3A.42	42 weeks gestation of pregnancy
Z3A.49	Greater than 42 weeks gestation of pregnancy
Z64.1	Problems related to multiparity
Z86.32	Personal history of gestational diabetes

Contraceptive Diagnosis List	
ICD-10 Code(s)	Description
Z30.011	Encounter for initial prescription of contraceptive pills
Z30.012	Encounter for prescription of emergency contraception
Z30.013	Encounter for initial prescription of injectable contraceptive
Z30.014	Encounter for initial prescription of intrauterine contraceptive device
Z30.015	Encounter for initial prescription of vaginal ring hormonal contraceptive
Z30.016	Encounter for initial prescription of transdermal patch hormonal contraceptive device
Z30.017	Encounter for initial prescription of implantable subdermal contraceptive
Z30.018	Encounter for initial prescription of other contraceptives
Z30.019	Encounter for initial prescription of contraceptives, unspecified
Z30.09	Encounter for other general counseling and advice on contraception
Z30.2	Encounter for sterilization
Z30.40	Encounter for surveillance of contraceptives, unspecified
Z30.41	Encounter for surveillance of contraceptive pills
Z30.42	Encounter for surveillance of injectable contraceptive
Z30.430	Encounter for insertion of intrauterine contraceptive device
Z30.431	Encounter for routine checking of intrauterine contraceptive device
Z30.432	Encounter for removal of intrauterine contraceptive device
Z30.433	Encounter for removal and reinsertion of intrauterine contraceptive device
Z30.44	Encounter for surveillance of vaginal ring hormonal contraceptive device
Z30.45	Encounter for surveillance of transdermal patch hormonal contraceptive device
Z30.46	Encounter for surveillance of implantable subdermal contraceptive
Z30.49	Encounter for surveillance of other contraceptives
Z30.8	Encounter for other contraceptive management
Z30.9	Encounter for contraceptive management, unspecified